Pharmaceutisch Weekblad

, Volume 6, Issue 1, pp 22–26 | Cite as

Leukocyte, leukaemia and drugs

  • R. Willemze
Congress ‘Blood and Drugs’


A review is given about the normal kinetics of granulopoiesis and the possible effects of drugs on the normal haematopoiesis. Subsequently some properties of acute leukaemia are described, and finally some remarks are made about management policies of acute leukaemia and the effects of cytostatic drugs on normal and leukaemic haematopoiesis.


Public Health Internal Medicine Management Policy Acute Leukaemia Cytostatic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cartwright GD. Investigation of leukocyte production and survival using C14 and P32. In: Stohlman Jr F, ed. The kinetics of cellular proliferation. New York: Grune & Stratton, 1959:183.Google Scholar
  2. 2.
    Dancey JT, Deubelbeiss KA, Harker LA, et al. Neutrophil kinetics in man. J Clin Invest 1976;58:705–15.PubMedGoogle Scholar
  3. 3.
    Cronkite EP, Vincent PC. Granulopoiesis. Ser Haematol 1969;2:3.Google Scholar
  4. 4.
    Athens J. Neutrophilic granulocyte kinetics and granulopoiesis. In: Gordon AS, ed. Regulation of hematopoiesis. Vol. 2. New York: Appleton-Century-Crofts, 1970:1143.Google Scholar
  5. 5.
    Lobue J. Analysis of normal granulocyte production and release. In: Gordon AS, ed. Regulation of hematopoiesis. Vol. 2. New York: Appleton-Century-Crofts, 1970:1167.Google Scholar
  6. 6.
    Mauer AM. Diurnal variation of proliferative activity in human bone marrow. Blood 1965;26:1–7.PubMedGoogle Scholar
  7. 7.
    Craddock CG, Perry S, Lawrence JS. Control of the steady state proliferation of leukocytes. In: Stohlman Jr F, ed. The kinetics of cellular proliferation. New York: Grune & Stratton, 1959:242.Google Scholar
  8. 8.
    Craddock CG, Perry S, Lawrence JS. The dynamics of leukopoiesis and leukocytosis studied by leukophoresis and isotopic techniques. J Clin Invest 1956;35:285–96.PubMedGoogle Scholar
  9. 9.
    O'Fallan WM, Walker RI, Van der Vaart HR. The study of granulocyte kinetics by mathematical analysis of DNA labeling. Acta Biotheor 1971;20:95–124.Google Scholar
  10. 10.
    Mauer AM, Athens JW, Warner HR, et al. An analysis of leukocyte radioactivity curves obtained with radioactive diisopropylfluorphosphate (DFP32). In: Stohlman Jr F, ed. The kinetics of cellular proliferation. New York: Grune & Stratton, 1959:231.Google Scholar
  11. 11.
    Athens JW, Mauer AM, Ashenbrucker H, et al. Leukokinetic studies. I. A method for labeling leukocytes with diisopropylfluorphosphate (DFP32). Blood 1959; 14:303–33.PubMedGoogle Scholar
  12. 12.
    Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest 1961;40:989–95.PubMedGoogle Scholar
  13. 13.
    Dresch C, Najean Y, Bauchet J. Kinetic studies of51Cr and DFP32 labelled granulocytes. Br J Haematol 1975;29:67–80.PubMedGoogle Scholar
  14. 14.
    Conheim J. The distribution of leukocytes in the vascular system. Acta Pathol Microbiol Scand 1938;suppl. 33:239.Google Scholar
  15. 15.
    Deubelbeiss KA, Dancey JT, Harker LA, et al. Neutrophil kinetics in the dog. J Clin Invest 1975;55: 833–9.PubMedGoogle Scholar
  16. 16.
    Finch SC. Granulocyte disorders-benign, quantitative abnormalities of granulocytes. In: Williams WJ, ed. Haematology, 2nd ed. New York: McGraw-Hill, 1977:717.Google Scholar
  17. 17.
    Frei III E, Frairech EJ. Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemotherapy 1965;2:269–95.Google Scholar
  18. 18.
    Ellison RR, Holland JF, Weil M. Arabinosyl cytosine. A useful agent in the treatment of acute leukemia in adults. Blood 1968;32:507–23.PubMedGoogle Scholar
  19. 19.
    Willemze R, Den Ottolander GJ, Heering KJ, et al. Behandeling van acute myeloïde leukemie bij volwassenen; een verantwoording over de jaren 1968 t.m. 1975. Ned Tijdschr Geneeskd 1977;121:1843–7.PubMedGoogle Scholar
  20. 20.
    Yates JP, Wallace HJ, Ellison RR, Holland JF. Cytosine arabinoside and daunorubicin therapy in acute nonlymphocytic leukemia. Cancer Chemotherapy Rep 1973;57:485–8.Google Scholar
  21. 21.
    Gale RP, Cline MJ. High remission induction rate in acute myeloid leukemia. Lancet 1977;1:497–9.PubMedGoogle Scholar
  22. 22.
    Willemze R, Zwaan FE, Colpin GGD, Keuning JJ. High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 1982; 29:141–6.PubMedGoogle Scholar
  23. 23.
    Ellison RR, Glidewell O. Improved survival in adults with acute myelocytic leukemia. Proc Am Assoc Cancer Res 1979;20:161.Google Scholar
  24. 24.
    Omura GA, Vogler WR, Lynn MJ. A controlled clinical trial of chemotherapy vs BCG immunotherapy vs no further therapy in remission maintenance of acute myelogenous leukemia. Proc Am Clin Oncol A1977; Abstract C23:272.Google Scholar
  25. 25.
    Zwaan FE, Hermans J. Bone Marrow transplantation for leukaemia — European results in 264 cases. Exp Hematol 1982;10(suppl. 10):64–9.PubMedGoogle Scholar
  26. 26.
    Weinstein HJ, Mayer RJ, Rosenthal DS, et al. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980;303:473–8.PubMedGoogle Scholar
  27. 27.
    Preisler HD, Brecher M, Browman AP, et al. The treatment of acute myelocytic leukemia in patients 30 years of age and younger. Am J Hematol 1982;13:189–98.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1984

Authors and Affiliations

  • R. Willemze
    • 1
  1. 1.Division of Haematology, Department of MedicineLeiden University Medical CentreAA LeidenThe Netherlands

Personalised recommendations